Stockscreener 앱 받기
16.50
0.12%
0.02
시간 외 거래:
16.50
Viatris Inc 주식(VTRS)의 최신 뉴스
TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call - Yahoo Finance
U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain - marketscreener.com
FDA accepts Viatris application for fast-acting meloxicam - Investing.com
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - PR Newswire
Shareholders that lost money on Viatris Inc.(VTRS) should contac - GuruFocus
Understanding Momentum Shifts in (VTRS) - Stock Traders Daily
Viatris Inc (VTRS) Stock Down 4.5% but Still Overvalued -- GF Sc - GuruFocus
Viatris Shareholders Approve Directors, Pay and Auditor - TipRanks
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris (VTRS) investors elect full board and approve 2025 pay, auditor - Stock Titan
Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)? - Yahoo Finance
Viatris CFO leaving Canonsburg pharma giant - MSN
Bacterial Vaginosis Drug Market Will Generate Booming Growth - openPR.com
Viatris Inc.Common Stock (NQ: VTRS - FinancialContent
Biosimilars Market is expected to Hit US$ 99.3 Billion by 2033 | - openPR.com
Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug - Law360
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises - Investing.com
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises By Investing.com - Investing.com South Africa
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says - Bloomberg Law News
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - sharewise.com
HHS officials considered banning SSRI antidepressantsreport - MSN
Viatris (VTRS) Is Up 10.6% After Q1 Beat, CFO Change And Outlook ReaffirmationWhat's Changed - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Transcript : Viatris Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08 - marketscreener.com
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade) (NASDAQ:VTRS) - Seeking Alpha
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance - Yahoo Finance
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris gears up to report Q1 earnings: What's in the cards? - MSN
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating (NASDAQ:VTRS) - Seeking Alpha
UBS Adjusts Viatris Price Target to $23 From $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Exploring the Healthcare Giant’s Valuation and Dividend Yield - DirectorsTalk Interviews
Viatris Announces Second Quarter 2024 Dividend - Quantisnow
Viatris Q1 2026 earnings preview: Caution remains around ongoing turnaround - MSN
Viatris Inc. stock rises Thursday, outperforms market - MSN
Viatris Inc. (NASDAQ:VTRS) Q1 2026 Earnings Call Transcript - Insider Monkey
Viatris Earnings Call Highlights Profits, Pipeline Momentum - The Globe and Mail
Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc. - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle - TradingView
Truist Financial Maintains Viatris(VTRS.US) With Buy Rating, Announces Target Price $20 - Moomoo
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Viatris: Q1 Earnings Snapshot - theheraldreview.com
Viatris Inc. Stock 12‑Month Price Target Raised to $17.25, Implies 1% Downside - TradingView
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference - BioSpace
Viatris Delivers Strong Q1 2026 Results, Reaffirms Guidance - The Globe and Mail
Viatris Inc. Stock 12‑Month Price Target Raised to $16.88, Implies 3% Downside - TradingView
5-Day Rally Sends Viatris Stock Up 16% - Trefis
Viatris Stock Rockets 16% With 5-Day Winning Streak - Trefis
Viatris stock hits 52-week high at $16.63 By Investing.com - Investing.com Nigeria
Viatris Q1 2026 Earnings Call Transcript - MarketBeat
Viatris Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Viatris (VTRS) Jumps As Targets Rise And Pipeline Delivers - timothysykes.com
Viatris Earnings: Stable Base Business and Pipeline Progression Mark a Solid Start to 2026 - Morningstar
0.76%
0.35%
자본화:
|
볼륨(24시간):